DEVELOPMENT OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WITH CALR-MUTATED
POSTER 26
PRIMARY MYELOFIBROSIS
Patryk Sobieralski, Maria Bieniaszewska and Jan Zaucha
Medical University of Gdańsk, Department of Hematology and Transplantology, Gdańsk, Poland
Historically, the development of secondary CML has only been casually described. Since then,
limited reports tried to analyze and scientifically explain the mechanisms behind this
phenomenon. Reported cases vary regarding presumed pathogenesis and clinical picture but
ultimately similarities can be found. Here we report a patient diagnosed with BCR-ABL1-
negative MPN (PMF) who, after over 10 years of observation and treatment, have developed
secondary CML. Our case differs considerably from other reports regarding both molecular
profile and response to treatment, evaluated through Next Generation Sequencing and RT-qPCR,
respectively. Up to our knowledge this is the first description of MPN with evolving
atypical clinical picture and coexistence of CALR mutation and Philadelphia-chromosome,
presumably in the same malignant clone. Additionally, the absence of JAK2 and ABL1 gene
mutations, along with poor response to TKI treatment, contrasts with cases reported
previously. Described case elucidates the molecular instability that occurs in patients with
MPNs. The aim of this report is to share our experiences and analyze the clonal evolution
process to further broaden the knowledge within this spectrum.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES